Altered immune cells clear childhood brain tumor in mice
Photo by Steve Fisch
Translating Stanford discoveries into individualized cancer care
Stanford Cancer Initiative is an ambitious program to transform the care experience of every cancer patient treated at Stanford. The Initiative combines the latest research and information management protocols with multi-disciplinary, patient-centered care to improve quality of life and overall health outcomes. Integrating leading-edge research and comprehensive care to dramatically change the prognosis and treatment of cancer.
The Stanford Cancer Institute has been designated a Comprehensive Cancer Center by the National Cancer Institute, a part of the National Institutes of Health and the world’s leading cancer research organization.
Designation as a Comprehensive Cancer Center signifies that the Stanford Cancer Institute maintains the highest level of scientific rigor, institutional support and coordination for the complete range of cancer-related research, including basic, translational, clinical and population-based science. The designation is recognition of the institute’s robust and integrated programs encompassing laboratory research, clinical care and community outreach and education.
The Institute’s mission is to support and coordinate the wide range of cancer-related activities — in basic, translational, clinical and population-based science — occurring at Stanford University, Stanford Health Care and Lucile Packard Children’s Hospital Stanford, along with its partner institution, the Cancer Prevention Institute of California. Its nearly 400 members include scientists and physicians from a wide range of disciplines, all collaborating to translate research advances into improved cancer treatments.
In mice, a fatal brainstem tumor was cleared by injecting it with engineered T cells that recognized the cancer and targeted it for destruction. The Stanford discovery is moving to human trials.
Cancer research that once involved years of painstaking work can now happen in months with a novel technique for studying cancer-related genes. The results reveal how combinations of mutations influence tumor growth.
With the help of a new radioactive tracer, doctors can predict with more than 80 percent accuracy how well a widely-used lung cancer drug will combat tumors, according to researchers at Stanford.